Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect

Stephanie Sisley,1,2 Ruth Gutierrez-Aguilar,3 Michael Scott,4 David A. D’Alessio,3 Darleen A. Sandoval,3 and Randy J. Seeley3

1Department of Pediatrics, Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA. 2Department of Pediatrics, Division of Nutrition, Baylor College of Medicine, Houston, Texas, USA. 3Department of Internal Medicine, Division of Endocrinology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 4Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Glucose control and weight loss are cornerstones of type 2 diabetes treatment. Currently, only glucagon-like peptide-1 (GLP1) analogs are able to achieve both weight loss and glucose tolerance. Both glucose and body weight are regulated by the brain, which contains GLP1 receptors (GLP1R). Even though the brain is poised to mediate the effects of GLP1 analogs, it remains unclear whether the glucose- and body weight–lowering effects of long-acting GLP1R agonists are via direct action on CNS GLP1R or the result of downstream activation of afferent neuronal GLP1R. We generated mice with either neuronal or visceral nerve-specific deletion of Glp1r and then administered liraglutide, a long-acting GLP1R agonist. We found that neither reduction of GLP1R in the CNS nor in the visceral nerves resulted in alterations in body weight or food intake in animals fed normal chow or a high-fat diet. Liraglutide treatment provided beneficial glucose-lowering effects in both chow- and high-fat–fed mice lacking GLP1R in the CNS or visceral nerves; however, liraglutide was ineffective at altering food intake, body weight, or causing a conditioned taste aversion in mice lacking neuronal GLP1R. These data indicate that neuronal GLP1Rs mediate body weight and anorectic effects of liraglutide, but are not required for glucose-lowering effects.

Introduction

Glucagon-like peptide-1 (GLP1) is a peptide produced both by intestinal enteroendocrine cells and a discrete population of hindbrain neurons. GLP1 acts through a G-protein–coupled receptor (GLP1R) expressed on pancreatic β cells, CNS neurons, and peripheral neurons (including hepatic vagal afferents from the nodose ganglia) (1). GLP1R activation improves glucose tolerance and causes weight loss (2). Thus, long-acting GLP1R agonists are clinically used to control glucose and body weight in type 2 diabetic patients (3). Despite the popularity of these drugs, considerable controversy surrounds which GLP1Rs mediate their beneficial effects. Multiple publications have shown central GLP1R activation decreases food intake and improves glucose tolerance while inhibition increases food intake and worsens glucose tolerance (4). However, there is also evidence that activation of GLP1R expressed on peripheral vagal afferents can decrease food intake and improve glucose tolerance (5, 6). Despite these known effects of GLP1, DPP4 inhibitors, which increase the longevity of native GLP1, produce negligible weight loss (3). Thus, it is unknown how long-acting GLP1R agonists mediate their anorectic effects and whether they are mediated in a manner similar to their glucose-lowering effects.

Results

To discriminate between the effects of GLP1R expression on peripheral versus central nerves, we developed mouse models with selective reduction of key GLP1R–expressing components of the central or peripheral nervous system. This was accomplished through the insertion of loxP sites surrounding exons 6 and 7 of the Glp1r gene (Figure 1A) and subsequent breeding to either nestin-Cre (7) or Phox2b-Cre (8) mice, respectively. Nestin is an intermediate filament protein expressed in neuroepithelial cells that, when used as a promoter for Cre expression, specifically disrupts the gene of interest in the brain (7, 9, 10). Mice with site-specific knockdown (KD) of the GLP1R in the CNS (nestin-Cre Glp1rΔnestin) showed markedly decreased Glp1r mRNA in the hypothalamus and brainstem compared with control mice, but no reduction in the nodose ganglion or lung (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI72434DS1). We also observed a decrease in pancreatic Glp1r expression (Supplemental Figure 1A). However, while some data show expression of nestin in pancreatic progenitor cells (11), it has not been shown to be present in endocrine cells (12). The gene for Glp1r is located in the nodose ganglia, a cell body of the vagus nerve, and the protein is found within neurons innervating the hepatic portal vein (13). Phox2b is a homeobox gene expressed in the autonomic nervous system, including the nucleus of the solitary tract and dorsomotor nucleus of the vagus (14). Thus, using a Cre-recombinase driven by a Phox2b promoter, we generated mice with site-specific KD of the GLP1R in visceral afferent and efferent nerves (Phox2b-Cre Glp1rΔphox2b, herein referred to as GLP1R KDΔPhox2b). Accordingly, GLP1R KDΔPhox2b had decreased expression of the Glp1r in the nodose ganglion, but no change in the hypothalamus or hindbrain (Supplemental Figure 1B).

Since endogenous GLP1 has been hypothesized to regulate food intake and body weight (6), we tested the role of CNS and vagal GLP1Rs in the regulation of food intake and body weight. In chow and high-fat diet conditions, body weight did not differ among GLP1R KDΔnestin, GLP1R KDΔPhox2b, or controls (Figure 1, B and D). Consistent with this, no differences existed in body composition (Figure 1, C and E). Although no differences existed in food intake versus central nerves, we developed mouse models with select—

Conflict of interest: David A. D’Alessio consults for Eli Lilly, Merck, Novo Nordisk, and Zealand. David A. D’Alessio receives research support from MannKind Pharmaceuticals, Sanofi-Aventis, and Ethicon Endo-Surgery. Darleen A. Sandoval serves on the scientific advisory board at Ethicon Endo-Surgery. Darleen A. Sandoval receives research support from Ethicon Endo-Surgery, Boehringer Ingelheim, and Novo Nordisk. Randy J. Seeley is a paid speaker for Novo Nordisk and Merck. Randy J. Seeley serves on scientific advisory boards for Novo Nordisk, Novartis, Angiochem, Zealand, Takeda, Eli Lilly, Boehringer Ingelheim, Eisai, and Forest Pharmaceuticals. Randy J. Seeley has equity in Zafgen. Citation for this article: J Clin Invest. 2014;124(6):2456–2463. doi:10.1172/JCI72434.
among the groups on high-fat diet (Figure 1F), we have observed conflicting data regarding the food intake of chow-fed GLP1R KDΔNestin mice. In separate cohorts of GLP1R KDΔNestin mice, we have seen either similar or increased food intakes when compared with controls (Supplemental Figure 2, A and B, respectively). These discrepancies will be the subject of future investigations. However, given the high degree of GLP1R KD in both strains of mice, these data suggest that CNS and vagal GLP1Rs are not necessary for the normal regulation of food intake or body weight.

Despite these data, long-acting GLP1R agonists are well documented as having potent food intake–reducing effects. Prior research has pointed to a role for central GLP1 signaling in the anorectic effects of long-acting GLP1R agonists, but the respective contributions of central versus vagal GLP1R is unclear. Thus, a crucial question is whether such agonists act directly in the CNS or on vagal afferents to mediate these effects. In response to an acute s.c. injection of liraglutide, control and GLP1R KDΔPhox2b chow-fed mice had significantly decreased food intake at 4 and 24 hours (Figure 2, A and B). However, acute liraglutide administration caused a modest reduction in food intake at 4 hours but not at 24 hours in GLP1R KDΔNestin mice (Figure 2, A and B). In a new cohort of high-fat–fed GLP1R KDΔNestin mice, we repeated this study and found that liraglutide was able to decrease food intake compared with saline, but this response was attenuated compared with that of controls (Figure 2, C and D). Thus, CNS but not vagal GLP1Rs are necessary for the full acute anorectic response to a long-acting GLP1R agonist.

Acute administration of either GLP1 or long-acting GLP1R agonists causes visceral illness, which is reflected in rodent models by a pronounced conditioned taste aversion (CTA) (15, 16). Whether this effect is the result of activation of GLP1Rs in the CNS or a secondary result of reduced gastric emptying is controversial. Thus, we next tested whether liraglutide caused a CTA in our mouse models. Both chow-fed control and GLP1R KDΔPhox2b mice developed a CTA to a novel flavor paired with liraglutide. However, the pairing had no effect in GLP1R KDΔNestin mice, despite the ability to develop a CTA to lithium chloride (Figure 2E). Combined with our previous data, these results highlight the importance of CNS GLP1R in the acute anorectic effects of a long-acting GLP1R agonist.

Chronic administration of liraglutide continues to cause weight loss long after attenuation of its aversive effects (15). Thus, to understand the mechanism underlying weight loss associated with chronic administration of a long-acting GLP1R agonist (17), we administered liraglutide or saline daily for 15 days in these mouse models after 5 weeks of high-fat feeding. GLP1R KDΔNestin mice treated with liraglutide lost more weight than saline controls, but significantly less weight than liraglutide-treated GLP1R KDΔPhox2b or control mice (Figure 3, A and B). The body weight loss was proportional to the food intake changes observed with chronic liraglutide treatment (Figure 3C). Over the last 7 days of treatment, liraglutide decreased food intake in GLP1R KDΔPhox2b and control mice, but not in GLP1R KDΔNestin mice (Figure 3D). Liraglutide treatment also significantly decreased fat mass in both control
and GLP1R KD\textsuperscript{Phox2b} mice but not in GLP1R KD\textsuperscript{Nestin} mice (Figure 3E). There were no significant differences in lean mass across groups or treatments (Figure 3F). Together, these data show that CNS but not vagal GLP1R are necessary for the chronic anorectic and weight-lowering effects of liraglutide.

Although GLP1 has been widely hypothesized to lower glucose by increasing β cell insulin secretion, other data implicate vagal and CNS GLP1R contributions (13, 18). We performed both oral and i.p. glucose tolerance tests (GTTs) to assess the role of the central and vagal CNS GLP1R in endogenous GLP1 signaling. GLP1R KD\textsuperscript{Nestin} mice had no differences in oral or i.p. glucose tolerance compared with controls whether studied under chow- or high-fat–fed conditions (Figure 4, A–I). The chow-fed oral GTT was run in a separate cohort of mice without the availability of concurrent analysis of GLP1R KD\textsuperscript{Phox2b} mice. GLP1R KD\textsuperscript{Phox2b} did not show any differences in glucose tolerance in the chow-fed i.p. GTT or high-fat diet fed i.p. and oral GTTs (Figure 4, A–I). During the i.p. GTT on high-fat–fed mice, there was no interaction of genotype on insulin secretion at baseline or at 15 minutes (Figure 4F).

Homeostasis model assessment estimated insulin resistance (HOMA-IR) calculations, a measure of insulin resistance, also found no differences at baseline, nor were there differences in the insulin times glucose product at the 15-minute time point (data not shown). Thus, these data imply that neither CNS nor vagal GLP1R are necessary for the physiological regulation of glucose.

Given the previously published studies on the effects of GLP1 in the brain on glucose homeostasis (1, 13), it is reasonable to hypothesize that the actions of long-acting GLP1 agonists to improve glucose regulation are not limited to their direct actions on β cells. Thus, we next tested the necessity of CNS or vagal GLP1R to mediate the glucose-lowering effects of liraglutide. Liraglutide caused significant decreases in glucose excursions in all genotypes during i.p. GTTs after both acute and chronic administration (Figure 5, A and B). There was no effect of genotype on insulin levels during an i.p. GTT after 14 days of liraglutide (measured at 0 and 15 minutes after i.p. glucose) (Figure 5C). These data demonstrate that neither vagal nor CNS GLP1R are necessary for the glucose-lowering effects of liraglutide and suggest that these effects are also independent of insulin concentrations.

Discussion
These data are the first, to our knowledge, to identify tissue-specific effects of CNS GLP1Rs on body weight and glucose regulation. This information is critical to understanding both the physiological relevance of the GLP1 system and the mechanism of action of GLP1 analogs. Given the high degree of tissue-specific GLP1R KD in both strains of our mice, our data suggest that CNS and vagal GLP1R are not necessary for the normal regulation of food intake or body weight. This stands in contrast to other approaches showing decreased food intake with direct CNS GLP1R agonism (19).
or increased food intake with CNS GLP1R antagonism or KD (6). However, our data complement findings from whole-body Glp1r male KO mice, which have limited differences in food intake or body weight (20, 21). We do note that there may be a role for CNS GLP1R signaling in the regulation of food intake, since we have found differing results across multiple cohorts of mice. Importantly, we have never observed a difference in body weight or body fat. This implies that either these alterations in food intake are highly transient or compensated for via changes in energy expenditure. Future work will need to address this issue.

Previous data on the role of the vagus in GLP1 signaling is controversial, with some showing decreased GLP1/GLP1R agonist–mediated anorexia after vagotomy (5, 22, 23) and others demonstrating no effect of vagotomy in GLP1-mediated anorexia (15, 24). Interestingly, we find that GLP1Rs in the nodose ganglia of the vagus nerve are not necessary for the anorectic effects of a long-acting GLP1R agonist. This is the only approach that specifically targets the GLP1R on the vagus nerve without altering vagal afferent or efferent signaling activated by other substances. Thus, this approach gives more conclusive evidence that long-acting GLP1R agonists do not require substantial vagal GLP1R signaling for their anorectic effects.

Recent evidence indicates that the anorectic effects of exendin-4 are mediated entirely by the GLP1R (25). Here, we found that GLP1R KDnestin are highly resistant to the food intake and body weight lowering effects of liraglutide, supporting an important role for CNS GLP1R in mediating these effects. It should be noted that Cre driven by the nestin promoter has been widely used for loss-of-function of specific genes in the CNS, but it is expressed in other tissues, as evidenced by the reduced GLP1R in the pancreas of GLP1R KDnestin animals (11, 12). However, it is unlikely that other tissues targeted by nestin are likely to make large contributions to the effects of GLP1 analogs on these behavioral endpoints.

We and others have shown previously that CNS pharmacological blockade of the GLP1R increases food intake (19, 26) and that central GLP1Rs are important in the anorectic effects of peripheral liraglutide (5). Additionally, there are published data showing that liraglutide can cross the blood-brain barrier (27). Interestingly, on a chow diet, we saw no acute effect of liraglutide on food intake in GLP1R KDnestin animals, but on a high-fat diet we saw an attenuated effect at 24 hours. It is possible that this is a dose-dependent response, since liraglutide is dosed on body weight and thus high-fat fed animals received a higher dose. This attenuated effect on

---

**Figure 3**

Liraglutide requires CNS GLP1R for anorectic and weight-lowering effects in high-fat–fed mice. (A) Longitudinal body weights of Glp1r mutant mice treated with a long-acting GLP1R agonist or saline. (B) Cumulative weight loss of 14 days. (C) Longitudinal 14-day cumulative food intake of mice. (D) Total food intake during last 7 days of treatment. (E) Fourteen-day fat-mass change of mice. (F) Fourteen-day lean-mass change in mice. Black, controls; red, GLP1R KDnestin; gray, GLP1R CKDphox2b; solid, saline treatment; patterned, liraglutide treatment. Statistical analysis was with 2-way ANOVA with Tukey’s post-hoc with repeated measures (A and C) or without repeated measures (B and D–F). * p < 0.05 compared with saline treatment, same genotype unless otherwise indicated.
food intake was apparent during chronic liraglutide treatment as well. The decrease in body weight after liraglutide treatment mirrors the decrease in food intake in the GLP1R KDΔNestin mice. Thus, it is likely that the body weight effects of GLP1R agonists are driven by their effects on food intake. To put it in numbers, in GLP1R KDΔNestin animals, liraglutide treatment resulted in 24.76 fewer kcal ingested and 2.26 g less body fat than saline treatment. The 2.26 g body fat would equate to 20.38 kcal in intake, meaning there are only 4.38 kcal unaccounted for in the 14-day treatment course. This could be a result of inherent measurement inaccuracy in the food intake; however, we cannot exclude small differences in energy expenditure. Additionally, recent clinical literature demonstrates that weight loss secondary to GLP1R agonists can be explained via alterations in energy intake without effects on energy expenditure (28, 29). Regardless of their limited role in normal body weight, these data do point to an important role for CNS GLP1Rs in mediating food intake, body weight, and body fat responses to a long-acting GLP1R agonist.

Interestingly, these data do not implicate CNS or vagal GLP1Rs in the glucose-lowering effects of a long-acting GLP1R agonist. Previous data suggested that the hindbrain was important for GLP1’s glucose-lowering effects (6, 30, 31). Reduced expression of proopiomelanocortin in the hindbrain resulted in worsened glucose tolerance in high-fat–fed rats (6), but this may have been secondary to weight gain. The portal vein, which is innervated by the nodose ganglia and robustly expresses GLP1R, has also been hypothesized to contribute to endogenous GLP1’s actions (13). Local administration of GLP1R antagonists in the portal vein reduced normal glucose tolerance more than the same dose delivered into the general circulation (13). Furthermore, systemic GLP1R mediation of glycemic control has been shown to require vagal afferent fibers (23). Conversely, a blood-brain barrier–impermeable GLP1 analog increased neuronal activation in key hindbrain regions and lowered glucose excursions without an effect on body weight (30, 31). Importantly, the current approach specifically reduces GLP1R signaling in vagal afferents without altering the integrity of other vagal afferent or efferent signals. Thus, in our model, important elements of glucose regulation such as gastric emptying are still intact (32). Our data conflict with published reports showing an improvement in glucose tolerance and muscle glucose utilization after intracerebroventricular GLP1R antagonism with exendin 9–39 (33). However, this report used a high-fat (72%), carbohydrate-free diet, which is very different from the diet used in these studies, making direct comparisons difficult.

The current data do not find an effect of a GLP1R agonist on insulin secretion. This result comes with important caveats. It
is possible that 15 minutes may simply have not been the ideal time point to see the impact of liraglutide on insulin secretion and therefore this limits our ability to assess the impact of the GLP1R KD. Nevertheless, our data show that neither CNS nor vagal GLP1R are necessary for the ability of a long-acting GLP1R agonist to improve glucose tolerance.

In conclusion, these data highlight the important differences between the physiological effects of the endogenous GLP1 system and GLP1-based therapies. CNS and vagal GLP1Rs are not necessary for normal food intake, body weight regulation, or normal glucose tolerance. Vagal GLP1Rs also have little impact on GLP1R agonist–induced regulation of food intake and body weight. However, CNS GLP1Rs are necessary for the food intake, weight loss effects, and CTA effects of a long-acting GLP1R agonist. Identifying the key receptors for the effects of GLP1-based therapies holds promise for understanding the differences that exist in the clinical actions of long-acting GLP1 agonists and DPP-4 inhibitors (3) as well as designing more effective therapies that target key aspects of the GLP1 system to increase their effectiveness. Most importantly, these data show the importance of CNS action of antidiabetic therapies in order to also promote weight loss in diabetic patients.

Methods

Animals. Male mice were singly housed and maintained on a 12-hour light/12-hour dark cycle with food ad libitum, unless otherwise noted. Animals were initially placed on chow diet (Harlan Teklad no. 7012; 3.1 kcal/g, 25% protein, 17% fat, 58% carbohydrates per kcal), and studies were started after 8 weeks of age using age-matched mice. Mice received acute food intake studies and an i.p. GTT and were then placed on a high-fat, high-sucrose diet (Research Diets no. D12331; 5.56 kcal/gm, 16% protein, 58% fat, 26% carbohydrates per kcal) for 4 weeks (age range 13–25 weeks, average age 16 weeks). Mice received an oral GTT after 4 weeks of high-fat feeding, recovered for an additional week, and then underwent a chronic 2-week study. A separate cohort of male GLP1R KD

Generation of Glp1r conditional KO mice. A Glp1r conditional KO mouse was generated by introducing a loxP site on either side of exons 6 and 7 of the Glp1r gene (ref. 34 and Figure 1A). The Glp1r targeting vector was electroporated into 129 ES cells. Targeted Glp1r ES clones were identified by Southern blotting. Positive ES clones were injected into blastocysts to generate chimera by the ES core at the University of Cincinnati. Germ-line transmission was verified in agouti mice, and then these mice were bred to Flp-recombinase mice (Jackson Laboratory, stock number 003800, C57BL/6) to remove the neomycin resistance cassette. Subsequently, these mice were bred to C57BL/6 mice to remove the Flp gene before breeding to Cre mice. We generated neuronal KD of the GLP1R by breeding the floxed mice with nestin-Cre mice (Jackson Laboratories, no. 003771) (35) and nodose-specific KD by breeding to Phox2b-Cre mice (a gift from Joel Elmquist, University of Texas Southwestern, Dallas, Texas, USA) (36).

Breeding. Mice heterozygous for both the Cre (nestin or Phox2b) and Glp1r floxed gene were bred together to produce mice with Cre-specific loss of the Glp1r gene and littermate controls. We used only male nestin-Cre mice for breeding and performed DNA copy number analysis (TaqMan Copy Number Assays; Applied Biosciences) to verify the absence of the transmission of a germline deletion (7, 37) that is common in females and less frequent (~10% in our studies) in males. Initially, 4 different control groups were analyzed: (a) Glp1r

Conclusions. Identifying the key receptors for the effects of GLP1-based therapies holds promise for understanding the differences that exist in the clinical actions of long-acting GLP1 agonists and DPP-4 inhibitors (3) as well as designing more effective therapies that target key aspects of the GLP1 system to increase their effectiveness. Most importantly, these data show the importance of CNS action of antidiabetic therapies in order to also promote weight loss in diabetic patients.

Validation. To validate proper gene targeting, mice were sacrificed by CO2 asphyxiation and tissues (brain, lung, liver, pancreas, nodose ganglia) were rapidly removed and frozen. Tissue RNA was extracted using a QIAGEN RNeasy kit. cDNA was isolated, and real-time quantitative PCR (qPCR) was performed using a TaqMan 7900 Sequence Detection System with TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays (all from Applied Biosystems). Relative mRNA expression for the Glp1r using a primer/probe targeted to exons 6 and 7 of the Glp1r gene (Mm00470859_cn; Applied Biosystems) was calculated relative to L32 using the ΔACT method (38).

Food intake studies. For all acute food intake studies, mice were fasted 4 hours prior to their dark cycle in order to increase the sensitivity of detecting anorectic responses without causing compensatory hyperphagia (39). During acute food intake studies, liraglutide (Novo Nordisk; 400 μg/kg) or saline (10 ml/kg) was injected s.c. beginning 1 hour prior to the dark cycle in a counterbalanced approach. This dose was based on advisement by Novo Nordisk and is in line with previously published effective doses. Food was measured at baseline and 1, 2, 4, and 24 hours after lights out. Body weights were measured at baseline and at 24 hours. A crossover study was performed the following week and the results pooled.

CTA test. Weight-randomized mice were deprived of water for 24 hours and then given access to 0.15% of saccharin solution (presented on the opposite side of the normal location of the water bottle) for 2 hours. They...
then received saline, liraglutide, or LiCl (0.15 M in a volume equivalent to 2% of each animal’s body weight, s.c.); this was followed by removal of the saccharin bottle and replacement of the water bottle. The dose of liraglutide was approximately 400 μg/kg. The following day, animals were water deprived. Twenty-four hours later, water and saccharin bottles were returned to their previous locations. Fluid intake was measured 24 hours after access to the bottles.

**GTT.** During the acute i.p. GTT, mice were fasted for 4 hours. At t = −120 minutes, mice were given liraglutide (400 μg/kg) or saline (10 μl/kg) s.c. At t = 0 minutes, mice were given an i.p. injection of 1.5 g/kg 25% dextrose. Blood glucose was measured by tail blood sampling at −180, 0, 15, 30, 45, 60, and 120 minutes. 40 μl blood was collected from a subset of mice (n = 5/group) into heparinised tubes at 180 prior to and 15 minutes after glucose administration and immediately placed on ice. An additional i.p. GTT was performed at the conclusion of the chronic study as above, except mice were given liraglutide (1000 μg/kg) or saline s.c. An oral GTT was performed as above for the acute i.p. GTT, except a flat dose of 50 mg (1.6 g/kg) D2SW glucose gavage (40) was given at t = 0 minutes.

**Insulin analysis.** Serum collected from a GTT was analyzed using an ultra-sensitive mouse insulin ELISA kit (Crystal Chem) per the manufacturer’s protocol for a low-range assay.

**Chronic study.** Male diet-induced obese mice were randomized by weight and assigned to receive either liraglutide or saline for 15 days. Mice were injected at least 1 hour prior to the dark cycle with liraglutide as follows: 300 μg/kg on day 0, 600 μg/kg on day 1, and 1000 μg/kg on days 2 to 16. All injections were given s.c. as a 10 ml/kg bolus. 24-hour food intake measurements and body weights were performed daily. On day 14, a GTT was performed as above.

---

**Body composition analysis.** Mice underwent body composition analysis (EchoMRI) prior to placement on high-fat diet and on day 16 of the chronic study.

**Statistics.** Statistical analyses were performed with Prism (GraphPad Software v6). Statistical tests performed are included in each figure legend. Data are presented as mean ± SEM. Statistical significance was set at P < 0.05 for all analyses. Number of animals for each experiment is listed in Supplemental Methods.

**Study approval.** All studies were approved by the University of Connecticut Institutional Animal Care and Use Committee.

---

**Acknowledgments.** We would like to acknowledge the superior technical assistance of Bailing Li, Joyce Sorrell, Emily Matter, Alfor Lewis, Eric Smith, and April Haller. We would also like to thank Joel Elmqvist (University of Texas Southwestern) for making the Phox2b-cre mice available for these experiments. These studies were funded by the following NIH grants: 1F32DK091077-01A1 (to S. Sisley); DK057900 (to D.A. D’Alessio); DK082480 (to D.A. D’Alessio); DK093848 (to R.J. Seeley) and DK082480 (to D.A. Sandoval). R.J. Seeley and D.A. D’Alessio also received funding from Nordo Nordisk.

---

**Received for publication July 29, 2013, and accepted in revised form February 27, 2014.**

**Address correspondence to:** Stephanie Sisley, 1100 Bates St., Houston, Texas 77030, USA. Phone: 713.798.0391; Fax: 713.798.7057; E-mail: Stephanie.sisley@bcm.edu.